BridgeBio's Attruby Appears to Outshine Pfizer's Vyndamax in Crucial Real-World Study for ATTR-CM The Unfolding Story of Hope: BridgeBio's Double Victory in the Battle Against Rare Disease Biotech's Pulse Check: AI Rises, a Cancer Test Stumbles, and a Rare Disease Shines Acoramidis: A Beacon of Hope for Rare Heart Disease Patients with Rapid Cardiac Benefit